Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- C-terminus C-terminal intracellular plasma membranes whole cells LTB4R1 receptors antiserum antibodies leukotrienes neutrophils inflammation antisera flow cytometry immunocytochemistry icc WB western blots blotting immunohistochemistry ihc chronic pancreatitis pancreatic cancers pancreas atherosclerosis immunoblotting FC
- Product Overview:
The leukotriene B4 receptor 1 (BLT1 receptor), cloned from HL-60 human leukemia cells, has 352 amino acids and seven putative membrane-spanning domains.{4425} The primary structure of the receptor is identical to that of a putative purinoceptor, P2Y7, which binds to micromolar concentrations of ATP.{4424} Northern blotting reveals that the BLT1 receptor is highly expressed in leukocytes, U937 cells, and to a much lower extent in spleen and thymus.{4425} Sheep lung membranes have also been identified as a rich source for receptor isolation and purification.{4640} A second LTB4 receptor, BLT2, has recently been cloned and characterized.{8280,8525,8743} Cayman Chemical’s BLT1 receptor polyclonal antiserum is made against a peptide from the C-terminus of the BLT1 receptor, which is located on the intracellular side of the plasma membrane. Therefore, when performing studies on whole cells, permeabilization of the cells is required for the antibody to enter the cytosol. The antiserum is recommended for immunohistochemical analysis of BLT1 receptor expression in tissues of human and bovine origin. Successful recognition of the overexpression of BLT1 in pancreatic ductal cells of human chronic pancreatitis and pancreatic cancer patients has been documented using this antiserum.{4425}
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.